Stock EQL EQL PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials EQL Pharma AB

Equities

EQL

SE0005497732

Drug Retailers

Delayed Nasdaq Stockholm
Other stock markets
 11:50:08 16/07/2024 BST 		5-day change 1st Jan Change
56.4 SEK -0.35% Intraday chart for EQL Pharma AB -5.05% +68.86%

Valuation

Fiscal Period: March 2023 2024 2025 2026
Capitalization 1 1,087 1,229 1,645 -
Enterprise Value (EV) 1 1,087 1,329 1,704 1,678
P/E ratio 35.3 x 55.7 x 23 x 18.4 x
Yield - - - -
Capitalization / Revenue - 4.65 x 3.84 x 3.36 x
EV / Revenue - 5.03 x 3.98 x 3.42 x
EV / EBITDA - 31.5 x 15.4 x 12.6 x
EV / FCF - -17.1 x 100 x 32.9 x
FCF Yield - -5.85% 1% 3.04%
Price to Book - 6.92 x 5.94 x 5.1 x
Nbr of stocks (in thousands) 29,064 29,064 29,064 -
Reference price 2 37.40 42.30 56.60 56.60
Announcement Date 11/05/23 14/05/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2023 2024 2025 2026
Net sales 1 - 264.2 428.5 490
EBITDA 1 - 42.16 110.4 133
EBIT 1 - 32.62 96.82 119
Operating Margin - 12.35% 22.59% 24.29%
Earnings before Tax (EBT) 1 - 28.6 89.9 112
Net income 1 30.92 22.7 71.6 89
Net margin - 8.59% 16.71% 18.16%
EPS 2 1.060 0.7600 2.465 3.070
Free Cash Flow 1 - -77.7 17 51
FCF margin - -29.41% 3.97% 10.41%
FCF Conversion (EBITDA) - - 15.4% 38.35%
FCF Conversion (Net income) - - 23.74% 57.3%
Dividend per Share 2 - - - -
Announcement Date 11/05/23 14/05/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2024 Q4 2025 Q1 2025 Q2 2025 Q3 2025 Q4
Net sales 1 78.13 80 86 96 104
EBITDA 1 10.79 15 20 23 29
EBIT 1 8.373 12 17 20 26
Operating Margin 10.72% 15% 19.77% 20.83% 25%
Earnings before Tax (EBT) 1 5.947 10 15 18 24
Net income 1 4.693 8 12 15 19
Net margin 6.01% 10% 13.95% 15.62% 18.27%
EPS 2 0.1600 0.2800 0.4100 0.5100 0.6600
Dividend per Share - - - - -
Announcement Date 14/05/24 - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: March 2023 2024 2025 2026
Net Debt 1 - 99.6 59 33
Net Cash position 1 - - - -
Leverage (Debt/EBITDA) - 2.363 x 0.5345 x 0.2481 x
Free Cash Flow 1 - -77.7 17 51
ROE (net income / shareholders' equity) - 13.7% 29.3% 32.2%
ROA (Net income/ Total Assets) - - - -
Assets 1 - - - -
Book Value Per Share 2 - 6.120 9.540 11.10
Cash Flow per Share - - - -
Capex 1 - 0.93 0.16 -
Capex / Sales - 0.35% 0.04% -
Announcement Date 11/05/23 14/05/24 - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for EQL Pharma AB

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Drug Retailers

1st Jan change Capi.
EQL PHARMA AB Stock EQL Pharma AB
+68.86% 155M
WALGREENS BOOTS ALLIANCE, INC. Stock Walgreens Boots Alliance, Inc.
-55.19% 10.1B
JD HEALTH INTERNATIONAL INC. Stock JD Health International Inc.
-46.55% 8.81B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED Stock Alibaba Health Information Technology Limited
-25.71% 6.65B
MATSUKIYOCOCOKARA & CO. Stock MatsukiyoCocokara & Co.
-4.16% 6.45B
CORPORATIVO FRAGUA, S.A.B. DE C.V. Stock Corporativo Fragua, S.A.B. de C.V.
+97.00% 5.35B
NAHDI MEDICAL COMPANY Stock Nahdi Medical Company
-2.92% 4.63B
CLICKS GROUP LIMITED Stock Clicks Group Limited
+8.08% 4.6B
YIFENG PHARMACY CHAIN CO., LTD. Stock Yifeng Pharmacy Chain Co., Ltd.
-32.12% 3.79B
REDCARE PHARMACY NV Stock Redcare Pharmacy NV
+7.52% 3.13B
Other Drug Retailers
  1. Stock Market
  2. Equities
  3. EQL Stock
  4. Financials EQL Pharma AB